Savara
SVRA
Savara (SVRA) news
Recent news
Tern - Announces settlement with general partner of SVV2 for all claims and liabilities
AInvest Wire · 2d agoSavara Inc.: JP Morgan initiates coverage with overweight rating; target price $12
JP Morgan has initiated coverage on Savara Inc. (NASDAQ: SVRA), assigning an "overweight" rating and setting a target price of $12 per share. The move signals the firm’s positive outlook on the biopharmaceutical company, which has been developing therapies for rare pulmonary diseases. While no…
AInvest Wire · 7d agoSavara - European and Australian patent offices grant Molbreevi patents until March 2041
AInvest Wire · Aug 11, 2026Savara announces European and Australian patent offices have granted patents for the liquid formulation of Molbrevi*, providing protection in Europe and Australia until March 2041
AInvest Wire · Jul 30, 2026Savara - Dave Lowrance to step down as chief financial and administrative officer effective July 15, 2026
AInvest Wire · Jun 8, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.